Gabapentin Capsule
Product Images NDC 71335-3140

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-3140). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Image 01)

Line graph displaying mean pain score over 8 weeks comparing Placebo and Gabapentin 3600 mg/day. The horizontal axis shows weeks from baseline through week 8; the vertical axis shows mean pain scores from 0 to 10. The graph indicates a 4-week dose titration period followed by a 4-week fixed dose period, with Gabapentin showing a decreasing pain score compared to placebo.*

FDA Label Image

Figure 2 (Image 02)

Line graph depicting mean pain scores over 7 weeks for placebo and two Gabapentin dose groups (1800 mg/day and 2400 mg/day). The study period includes a 3-week dose titration phase followed by a 4-week fixed dose period, with pain scores decreasing over time, more pronounced in Gabapentin groups compared to placebo.*

FDA Label Image

Figure 3 (Image 03)

A bar graph titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and Gabapentin (GBP) doses in two studies. Study 1 shows 12% response for placebo and 29% for GBP 3600 mg. Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is indicated with p-values below 0.01 and 0.001.*

FDA Label Image

Image-04 (Image 04)

An illustration showing the formula for calculating creatinine clearance (CLCr). The formula includes variables for age in years, weight in kilograms, serum creatinine in mg/dL, and a factor of 0.85 for female patients.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of Gabapentin showing its molecular arrangement with a cyclohexane ring and functional groups including an amino group and a carboxylic acid group.*

FDA Label Image

Image-09 (Image 09)

A scatter plot comparing percentage difference versus daily dose in mg for three studies labeled a, b, and c. The x-axis represents daily dose ranging from 600 mg to 1800 mg, and the y-axis represents percentage difference ranging from 2% to 22%. Study a is represented by black squares, study b by gray squares, and study c by white squares. Each study has data points at 600 mg, 900 mg, 1200 mg, and 1800 mg doses, showing trends in the percentage difference across varying doses.*

FDA Label Image

Label (Lbl713353140)

Label for Gabapentin Capsules, USP 100 mg, oral dosage form. The label indicates 90 capsules per container, labeled as prescription only (Rx only). It is repackaged by Bryant Ranch Prepack, Inc. in Burbank, CA, and manufactured by ScieGen Pharmaceuticals, Inc. Storage instructions and warnings about dizziness are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.